Recent update on fixed combinations of antihypertensive agents

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

The amlodipine/atorvastatin single tablet has been shown to improve patients' achievement of national guideline recommended blood pressure and lipid target levels and exhibits a safety profile consistent with the parent compounds. The single tablet formulation has the potential to improve adherence and decrease prescription costs. These potential benefits are associated with important implications because hypertensive patients with additional risk factors represent a large proportion of those at risk for cardiovascular events. Combination low-dose drug treatment increases efficacy and reduces adverse effects. Fixed low-dose combination drug treatment increases efficacy and reduces adverse effects. This combination has greater potency and a similar side effect profile to monotherapy and represents a highly effective approach for attaining goal blood pressure levels using a therapeutic strategy that very effectively lowers blood pressure, is well-tolerated, and minimizes increasing doses of monotherapy-induced metabolic effects.

Original languageEnglish
Pages (from-to)237-243
Number of pages7
JournalKorean Circulation Journal
Volume38
Issue number5
DOIs
Publication statusPublished - 2008 May 1

Fingerprint

Antihypertensive Agents
Blood Pressure
Tablets
Drug Combinations
Prescriptions
Guidelines
Lipids
Safety
Costs and Cost Analysis
Pharmaceutical Preparations
Therapeutics
atorvastatin drug combination amlodipine

Keywords

  • Amlodipine
  • Atorvastatin
  • Combination drug therapy
  • Risk reduction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Recent update on fixed combinations of antihypertensive agents. / Park, Chang Gyu.

In: Korean Circulation Journal, Vol. 38, No. 5, 01.05.2008, p. 237-243.

Research output: Contribution to journalReview article

@article{43096d1a4c6b4efcb26feedda2d95706,
title = "Recent update on fixed combinations of antihypertensive agents",
abstract = "The amlodipine/atorvastatin single tablet has been shown to improve patients' achievement of national guideline recommended blood pressure and lipid target levels and exhibits a safety profile consistent with the parent compounds. The single tablet formulation has the potential to improve adherence and decrease prescription costs. These potential benefits are associated with important implications because hypertensive patients with additional risk factors represent a large proportion of those at risk for cardiovascular events. Combination low-dose drug treatment increases efficacy and reduces adverse effects. Fixed low-dose combination drug treatment increases efficacy and reduces adverse effects. This combination has greater potency and a similar side effect profile to monotherapy and represents a highly effective approach for attaining goal blood pressure levels using a therapeutic strategy that very effectively lowers blood pressure, is well-tolerated, and minimizes increasing doses of monotherapy-induced metabolic effects.",
keywords = "Amlodipine, Atorvastatin, Combination drug therapy, Risk reduction",
author = "Park, {Chang Gyu}",
year = "2008",
month = "5",
day = "1",
doi = "10.4070/kcj.2008.38.5.237",
language = "English",
volume = "38",
pages = "237--243",
journal = "Korean Circulation Journal",
issn = "1738-5520",
publisher = "Korean Society of Circulation",
number = "5",

}

TY - JOUR

T1 - Recent update on fixed combinations of antihypertensive agents

AU - Park, Chang Gyu

PY - 2008/5/1

Y1 - 2008/5/1

N2 - The amlodipine/atorvastatin single tablet has been shown to improve patients' achievement of national guideline recommended blood pressure and lipid target levels and exhibits a safety profile consistent with the parent compounds. The single tablet formulation has the potential to improve adherence and decrease prescription costs. These potential benefits are associated with important implications because hypertensive patients with additional risk factors represent a large proportion of those at risk for cardiovascular events. Combination low-dose drug treatment increases efficacy and reduces adverse effects. Fixed low-dose combination drug treatment increases efficacy and reduces adverse effects. This combination has greater potency and a similar side effect profile to monotherapy and represents a highly effective approach for attaining goal blood pressure levels using a therapeutic strategy that very effectively lowers blood pressure, is well-tolerated, and minimizes increasing doses of monotherapy-induced metabolic effects.

AB - The amlodipine/atorvastatin single tablet has been shown to improve patients' achievement of national guideline recommended blood pressure and lipid target levels and exhibits a safety profile consistent with the parent compounds. The single tablet formulation has the potential to improve adherence and decrease prescription costs. These potential benefits are associated with important implications because hypertensive patients with additional risk factors represent a large proportion of those at risk for cardiovascular events. Combination low-dose drug treatment increases efficacy and reduces adverse effects. Fixed low-dose combination drug treatment increases efficacy and reduces adverse effects. This combination has greater potency and a similar side effect profile to monotherapy and represents a highly effective approach for attaining goal blood pressure levels using a therapeutic strategy that very effectively lowers blood pressure, is well-tolerated, and minimizes increasing doses of monotherapy-induced metabolic effects.

KW - Amlodipine

KW - Atorvastatin

KW - Combination drug therapy

KW - Risk reduction

UR - http://www.scopus.com/inward/record.url?scp=47149115484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47149115484&partnerID=8YFLogxK

U2 - 10.4070/kcj.2008.38.5.237

DO - 10.4070/kcj.2008.38.5.237

M3 - Review article

VL - 38

SP - 237

EP - 243

JO - Korean Circulation Journal

JF - Korean Circulation Journal

SN - 1738-5520

IS - 5

ER -